Expression and role of microRNA-375 in cancer

Abstract

Liu Yang, Chen Nan, Pang Jinqiao, Xiong Chengxiu, Li Gaofeng. Expression and role of microRNA-375 in cancer[J]. Journal of International Oncology, 2016, 43(6): 442-444.

［1］ Shao Y, Geng Y, Gu W, et al. Prognostic significance of microRNA375 downregulation in solid tumors: a metaanalysis［J］. Dis Markers, 2014, 2014: 626185. DOI: 10.1155/2014/626185. ［2］ Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship［J］. Nat Rev Genet, 2012, 13(4): 271-282. DOI: 10.1038/nrg3162. ［3］ Shrestha S, Hsu SD, Huang WY, et al. A systematic review of microRNA expression profiling studies in human gastric cancer［J］. Cancer Med, 2014, 3(4): 878-888. DOI: 10.1002/cam4.246. ［4］ Wang L, Song G, Liu M, et al. MicroRNA375 overexpression influences P19 cell proliferation, apoptosis and differentiation through the Notch signaling pathway［J］. Int J Mol Med, 2016, 37(1): 47-55. DOI: 10.3892/ijmm.2015.2399. ［5］ Ding L, Xu Y, Zhang W, et al. MiR375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2［J］. Cell Res, 2010, 20(7): 784-793. DOI: 10.1038/cr.2010.79. ［6］ Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 1433zeta［J］. Cancer Res, 2010, 70(6): 2339-2349. DOI: 10.1158/00085472.CAN-09-2777. ［7］ Xu Y, Jin J, Liu Y, et al. Snailregulated miR375 inhibits migration and invasion of gastric cancer cells by targeting JAK2［J］. PLoS One, 2014, 9(7): e99516. DOI: 10.1371/journal.pone. 0099516. ［8］ Miao L, Liu K, Xie M, et al. MiR375 inhibits Helicobacter pyloriinduced gastric carcinogenesis by blocking JAK2STAT3 signaling［J］. Cancer Immunol Immunother, 2014, 63(7): 699-711. DOI: 10.1007/s00262-014-1550-y. ［9］ He XX, Chang Y, Meng FY, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo［J］. Oncogene, 2012, 31(28): 3357-3369. DOI: 10.1038/onc.2011.500. ［10］ Yang T, Zhao P, Rong Z, et al. Antitumor efficiency of lipidcoated cisplatin nanoparticles coloaded with microRNA375［J］. Theranostics, 2016, 6(1): 142-154. DOI: 10.7150/thno.13130. ［11］ Jung HI, Ahn T, Bae SH, et al. Astrocyte elevated gene1 overexpression in hepatocellular carcinoma: an independent prognostic factor［J］. Ann Surg Treat Res, 2015, 88(2): 7785. DOI: 10.4174/astr.2015.88.2.77. ［12］ Song S, Zhou J, He S, et al. Expression levels of microRNA375 in pancreatic cancer［J］. Biomed Rep, 2013, 1(3): 393-398. ［13］ Li W, Lebrun DG, Li M, et al. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma［J］. Chin J Cancer, 2011, 30(8): 540-550. DOI: 10.5732/cjc.011.10197. ［14］ Zhou J, Song S, He S, et al. MicroRNA375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway［J］. Int J Mol Med, 2014, 33(4): 950956. DOI: 10.3892/ijmm.2014.1638. ［15］ Xu L, Li M, Wang M, et al. The expression of microRNA375 in plasma and tissue is matched in human colorectal cancer［J］. BMC Cancer, 2014, 14(1): 714. DOI: 10.1186/1471-2407-14-714. ［16］ Wang Y, Tang Q, Li M, et al. MicroRNA375 inhibits colorectal cancer growth by targeting PIK3CA［J］. Biochem Biophys Res Commun, 2014, 444(2): 199204. DOI: 10.1016/j.bbrc.2014.01.028. ［17］ Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulinlike growth factor 1 receptor［J］. Gut, 2012, 61(1): 33-42. DOI: 10.1136/gutjnl-2011-300178. ［18］ Li X, Lin R, Li J. Epigenetic silencing of microRNA375 regulates PDK1 expression in esophageal cancer［J］. Dig Dis Sci, 2011, 56(10): 2849-2856. DOI: 10.1007/s10620-011-1711-1. ［19］ Isozaki Y, Hoshino I, Akutsu Y, et al. Usefulness of microRNA375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma［J］. Int J Oncol, 2015, 46(3): 1059-1066. DOI: 10.3892/ijo.2014.2789. ［20］ Shen Y, Wang P, Li Y, et al. miR375 is upregulated in acquired paclitaxel resistance in cervical cancer［J］. Br J Cancer, 2013, 109(1): 92-99. DOI: 10.1038/bjc.2013.308. ［21］ Shen Y, Zhou J, Li Y, et al. MiR375 mediated acquired chemoresistance in cervical cancer by facilitating EMT［J］. PLoS One, 2014, 9(10): e109299. DOI: 10.1371/journal.pone.0109299. ［22］叶文蔚, 李甫钥, 叶夏斌, 等. MiR375在子宫内膜癌HEC1B细胞中的生物学功能［J］. 实用医学杂志, 2013, 29(2): 177-180. ［23］ Jin Y, Liu YL, Zhang J, et al. The expression of miR375 is associated with carcinogenesis in three subtypes of lung cancer［J］. PLoS One, 2015, 10(12): e0144187. DOI: 10.1371/journal.pone.0144187.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

Expression and role of microRNA-375 in cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments